Sumitomo Dainippon Pharma

News Release

September 3, 2019

Sumitomo Dainippon Pharma Co., Ltd.

Sumitomo Dainippon Pharma Announces the Launch of Atypical Antipsychotic LATUDA® in China

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) announced today that Sumitomo Pharmaceuticals (Suzhou) Co., Ltd., its wholly-owned subsidiary in China, launches an atypical antipsychotic LATUDA® (generic name: lurasidone hydrochloride) in China for the treatment of adult patients with schizophrenia on September 3, 2019.

LATUDA® is an atypical antipsychotic agent created by Sumitomo Dainippon Pharma. Currently marketed under the LATUDA® brand name in the U.S. and other countries, it is one of the core products of the Sumitomo Dainippon Pharma Group. In China, the National Medical Products Administration (NMPA) granted an import drug license for this drug in January 2019, details of which can be found in the press release dated January 29, 2019.

With the launch of LATUDA®, a new treatment option for patients with schizophrenia in China, along with another atypical antipsychotic LONASEN® already launched in February 2018, Sumitomo Dainippon Pharma expects to make a greater contribution to the treatment of patients with schizophrenia in China.

（Reference）

About LATUDA®

LATUDA® is an atypical antipsychotic agent with an original chemical structure created by Sumitomo Dainippon Pharma and is believed to have an affinity for dopamine D_2, serotonin 5-HT_{2A}, and serotonin 5-HT_7 receptors where it has antagonist effects. In addition, LATUDA® is a partial agonist at the serotonin 5-HT_{1A} receptor and has no appreciable affinity for histamine H_1 or muscarinic M_1 receptors.

LATUDA® was approved for the treatment of schizophrenia in the U.S. in 2010, in Canada in 2012, in Switzerland in 2013, in Europe and Australia in 2014, in Taiwan, Russia, Singapore, Thailand, and Hong Kong in 2016, in Brazil and the UAE in 2017, and in Macau and Venezuela in 2018. It was also approved for the treatment of bipolar I depression in the U.S. in 2013, in Canada in 2014, and in Russia, Brazil, and Taiwan in 2017. In Japan, Sumitomo Dainippon Pharma submitted new drug applications for approval of the treatment of schizophrenia and bipolar depression on July 31, 2019.

Contact:
Corporate Communications
Sumitomo Dainippon Pharma Co., Ltd.
TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)